IBM (IBM) is showing how its quantum computing technology is starting to be used in healthcare and biology research. According to the tech company, quantum computing is reaching a point where it can handle problems that are too complex for traditional computers. Therefore, researchers are beginning to use it to study topics such as molecules and drug development. To support this progress, IBM is also involved in programs like the Quantum for Bio challenge.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade IBMInterestingly, this program brings together research teams from around the world to develop quantum-based solutions for healthcare. Notably, five of the six finalist teams used IBM’s quantum systems, which shows how important its technology is becoming. In addition, the program is backed by funding and focuses on building tools that could realistically run on quantum computers within the next three to five years. As a result, it helps move ideas from research into real-world testing.
Moreover, IBM believes that the future will involve combining quantum computing with traditional systems rather than replacing them. This hybrid approach allows scientists to use the strengths of both technologies to solve difficult problems more efficiently. Because of this, researchers would be able to analyze complex biological data faster and more accurately, which may lead to new medical discoveries. Overall, while quantum computing is still developing, IBM’s work shows it is becoming a practical tool for advancing healthcare and biology research.
Is IBM a Buy, Sell, or Hold?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on 11 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $310.88 per share implies 23% upside potential.
